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Neuropeptide Y rs16147 single nucleotide polymorphism is associated
with heavy drinking and severity of alcohol dependence.
Derick Vergne, Raymond Anton, Konstantin Voronin, Abraham Tiffany, Hugh Myrick 
Caleb Canders, Garrick Klaybor, Patrick Randall, Joe Schacht
Center for Drug and Alcohol Programs, 
Medical university of South Carolina, Charleston, SC
Introduction: A wide array of preclinical animal work has established a link between a
malfunctioning NPY system, anxiety, depression and alcohol dependence. In animals,
neuropharmacological and neuroanatomical studies have consistently shown the NPY
system to be 1) dysregulated in limbic areas strongly related to the stress system, and 2)
in behavioral animal models of excessive alcohol drinking. In humans the -485C>T
rs16147 SNP in the NPY promoter region, has been shown to increase plasma
neuropeptide Y. We wished to evaluate the relationship between NPY genotype and
alcohol consumption as well as to investigate whether this relationship is influenced by
levels of anxiety.
Methods: 191 non-treatment seeking alcoholics meeting DSM-IV criteria for alcohol
dependence (average age about 29, 80% male, 90% Caucasian, alcohol dependence
scale score mean of 14) were assessed with the Beck Anxiety Inventory (BAI), and also
for drinking (using the timeline-follow back calendar method), in the 90 days prior to a
blood draw for analysis of the NPY rs16147 SNP. DNA samples were genotyped for the
SNP rs16147 using a 5’ nuclease genotyping assay (TaqMan®; Applied Biosystems,
Foster City, CA). Amplification was performed via PCR (StepOne™ Real-Time PCR
System; Applied Biosystems). Four clusters were identified, representing CC and TT
homozygotes, CT heterozygotes, and no-DNA-template controls.
Results: The genotype frequencies were CC (25.7 %), CT (49.2 %) and TT (25.1 %). CC 
and CT were compared to   TT genotypes. . Individuals with two copies of the T allele 
showed significantly less heavy drinking days (p=0.017).The TT genotype was also 
associated with lower Alcoholism Severity (ADS score)(p=0.061), and those with TT 
showed less of an association between anxiety and alcohol symptoms (ADS score) 
compared to the CC and CT genotypes where the association was greater(p=0.012). 
Discussion: Our results show less heavy drinking when 2 copies of the minor allele 
(purported to increase NPY production) are present, consistent with animal models 
showing an inverse relationship between NPY expression and drinking behavior. The TT 
genotype was associated with lower alcohol severity, that became, more significant when 
anxiety was taken into account, suggesting that the tendency for NPY genotype to be 
associated with alcohol severity is partially dependent on the presence of anxiety. To our 
knowledge this is the first human genetics study showing an association between rs16147 
to human alcohol consumption in dependent drinkers. Further studies will elaborate on the 




A wide array of preclinical animal work has established a link between a
malfunctioning NPY system, anxiety, depression and alcohol dependence. In
animals, neuropharmacological and neuroanatomical studies have consistently
shown the NPY system to be 1) dysregulated in limbic areas strongly related to
the stress system, and 2) in behavioral animal models of excessive alcohol
drinking. In fact, NPY gene knock out animals drink more than wild type controls,
and rats selectively bred for high ethanol preference decreased their intake when
ICV NPY was administered. Anatomically, the amygdala appears to be a key site
for NPY action, as animals bred for high alcohol intake after alcohol deprivation
show a diminished alcohol drinking behavior with intra-amygdalar NPY injection.
Clinical studies linking NPY to mood and anxiety have shown decreased NPY
CSF levels in patients with diagnosed PTSD and depression, as well as a frontal
cortical decrease in NPY in post-mortem studies of depressive patients who
committed suicide. NPY genetic studies evaluating single nucleotide
polymorphisms (SNP) of the NPY gene have found an association between
changes in NPY expression, and drinking parameters in humans. The -485C>T
rs16147 SNP in the NPY gene promoter region, has been shown to increase
plasma neuropeptide Y levels. The presence of this SNP has also been
associated with anxiety and response to antidepressants in depressive subjects.
We wished to evaluate the relationship between NPY genotype and alcohol
consumption as well as to investigate whether this relationship is influenced
by levels of anxiety in non-treatment seeking alcoholics.
-Subjects (average age about 29, 80% male, 90% Caucasian, alcohol)
recruited from advertisements and assessed prior to participation in a bar-lab
and brain imaging study.
-Alcohol dependence by DSM-IV criteria (SCID-interview) but not seeking
treatment.
-No Axis 1 psychiatric disorders, no other substance dependence except
nicotine.
-Drinking during the 30 days prior ascertained with timeline
followback procedure.
-Beck Anxiety Inventory (BAI) used to measure anxiety
- Alcohol Drinking Scale (ADS) used to measure perception of alcohol drinking
effects
Blood drawn for DNA.
Subjects
METHODS - NPY rs16147
DNA ISOLATION
DNA was extracted from peripheral blood mononuclear cells using a Puregene
DNA Purification kit (Gentra Systems, Minneapolis, MN).  The amount of DNA extracted 
was quantified by absorbance spectroscopy (260 and 280 nm) and diluted to 5-20 ng/µL 
in 1X TE buffer.  DNA solutions were stored at 4°C.
5’ NUCLEASE GENOTYPING
DNA samples were genotyped for the SNP rs16147 using a 5’ nuclease 
genotyping assay (TaqMan®; Applied Biosystems, Foster City, CA).  TaqMan genotyping 
assays were predesigned (Applied Biosystems, identification No. C_2267279_10) and 
contained locus-specific primers and fluorogenic allele-specific probes.
The 5 µL reaction mixture consisted of 2.5 µL of 2X TaqMan® Universal PCR 
Master Mix, 0.25 µL of 20X assay mix, 8 µM detection probe for each allele, 36 µM 
forward and reverse primer each (all reagents supplied as TaqMan, Applied Biosystems), 
1.75 µL nuclease-free water (QIAGEN Sciences, Germantown, MD), and 5-20 ng of 
genomic DNA.  Amplification was performed via PCR (StepOne™ Real-Time PCR 
System; Applied Biosystems) using 48-well plates under the following conditions: 60°C 
for 30 seconds and 95°C for 10 minutes, followed by 40 cycles of 92°C for 15 seconds 
and 60°C for 1 minute.  During amplification, PCR software (StepOne™ v2.0; Applied 
Biosystems) measured SNP-specific fluorescence and genotyped each sample.  Four 
clusters were identified, representing CC and TT homozygotes, CT heterozygotes, and 
no-DNA-template controls. No significant deviation from Hardy-Weinberg equilibrium was 




Putative NPY circuit-rodent brain




Figure 1 Presence of 2 copies of the T allele is associated with 
decreased heavy drinking.
Figure 3. Relationship of Alcohol Severity 
and Anxiety.
P=0.017






Figure 2. The presence of two copies of the T allele 
confers an almost statistically significant decrease in 
alcohol severity.
Discussion/future directions:  Our results show less heavy drinking in 
TT NPY genotype individuals.   Since this genotype is purported to have 
increased NPY production these findings are consistent with animal 
models showing an inverse relationship between NPY expression and 
drinking behavior.  We also found a main effect of NPY genotype on 
alcohol severity (ADS scores) such that the TT genotype individuals had 
less alcohol dependence symptoms. This genotype effect on alcohol 
severity was mediated, at least to some degree, by the genotype effect 
on anxiety. 
Our results should be interpreted in light of the following:
- Since a large amount of preclinical and clinical data suggest that NPY 
has independent effects on anxiety and on alcohol consumption, our 
data might begin to suggest how some of these data might converge.
- Since NPY is expressed in areas of the brain involved with reward 
perception as well as stress/anxiety modulation, it is appealing to 
consider various brain mechanisms whereby alcohol and NPY might 
interact to produce their clinical effects.
- Future studies will clarify the role of the NPY system on drinking 
behavior and the nature of the relationship with stress/anxiety to 
modulate this behavior. This aim could be achieved by combining 
brain-imaging paradigms and genetic differences in clinical 
investigation and by evaluating drugs that work on the NPY system in 
clinical laboratory and treatment trials.
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